These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

9657 related articles for article (PubMed ID: 17932815)

  • 1. Tremelimumab, a fully human monoclonal IgG2 antibody against CTLA4 for the potential treatment of cancer.
    Tarhini AA; Kirkwood JM
    Curr Opin Mol Ther; 2007 Oct; 9(5):505-14. PubMed ID: 17932815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel therapies targeting the immune system: CTLA4 blockade with tremelimumab (CP-675,206), a fully human monoclonal antibody.
    Camacho LH
    Expert Opin Investig Drugs; 2008 Mar; 17(3):371-85. PubMed ID: 18321236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients.
    Hodi FS; Mihm MC; Soiffer RJ; Haluska FG; Butler M; Seiden MV; Davis T; Henry-Spires R; MacRae S; Willman A; Padera R; Jaklitsch MT; Shankar S; Chen TC; Korman A; Allison JP; Dranoff G
    Proc Natl Acad Sci U S A; 2003 Apr; 100(8):4712-7. PubMed ID: 12682289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer.
    Ribas A; Hanson DC; Noe DA; Millham R; Guyot DJ; Bernstein SH; Canniff PC; Sharma A; Gomez-Navarro J
    Oncologist; 2007 Jul; 12(7):873-83. PubMed ID: 17673618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tremelimumab.
    Drugs R D; 2010; 10(2):123-32. PubMed ID: 20698721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tremelimumab (CP-675,206): a fully human anticytotoxic T lymphocyte-associated antigen 4 monoclonal antibody for treatment of patients with advanced cancers.
    Tarhini AA; Kirkwood JM
    Expert Opin Biol Ther; 2008 Oct; 8(10):1583-93. PubMed ID: 18774925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical development of the anti-CTLA-4 antibody tremelimumab.
    Ribas A
    Semin Oncol; 2010 Oct; 37(5):450-4. PubMed ID: 21074059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of the CTLA4 blockade in the treatment of malignant melanoma.
    Cranmer LD; Hersh E
    Cancer Invest; 2007 Oct; 25(7):613-31. PubMed ID: 18027152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies.
    O'Day SJ; Hamid O; Urba WJ
    Cancer; 2007 Dec; 110(12):2614-27. PubMed ID: 18000991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab.
    Eroglu Z; Kim DW; Wang X; Camacho LH; Chmielowski B; Seja E; Villanueva A; Ruchalski K; Glaspy JA; Kim KB; Hwu WJ; Ribas A
    Eur J Cancer; 2015 Nov; 51(17):2689-97. PubMed ID: 26364516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with tremelimumab (CP-675,206).
    Ribas A
    Oncologist; 2008; 13 Suppl 4():10-5. PubMed ID: 19001146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.
    Ribas A; Camacho LH; Lopez-Berestein G; Pavlov D; Bulanhagui CA; Millham R; Comin-Anduix B; Reuben JM; Seja E; Parker CA; Sharma A; Glaspy JA; Gomez-Navarro J
    J Clin Oncol; 2005 Dec; 23(35):8968-77. PubMed ID: 16204013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Future directions in tumor immunotherapy: CTLA4 blockade.
    Gulley JL; Dahut WL
    Nat Clin Pract Oncol; 2007 Mar; 4(3):136-7. PubMed ID: 17327854
    [No Abstract]   [Full Text] [Related]  

  • 14. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma.
    Sanderson K; Scotland R; Lee P; Liu D; Groshen S; Snively J; Sian S; Nichol G; Davis T; Keler T; Yellin M; Weber J
    J Clin Oncol; 2005 Feb; 23(4):741-50. PubMed ID: 15613700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CTLA-4 blockade: autoimmunity as treatment.
    Kapadia D; Fong L
    J Clin Oncol; 2005 Dec; 23(35):8926-8. PubMed ID: 16204008
    [No Abstract]   [Full Text] [Related]  

  • 16. Phase I trial of an enhanced prostate-specific antigen-based vaccine and anti-CTLA-4 antibody in patients with metastatic androgen-independent prostate cancer.
    Theoret MR; Arlen PM; Pazdur M; Dahut WL; Schlom J; Gulley JL
    Clin Genitourin Cancer; 2007 Jun; 5(5):347-50. PubMed ID: 17645835
    [No Abstract]   [Full Text] [Related]  

  • 17. Treating cancer by targeting the immune system.
    Hwu P
    N Engl J Med; 2010 Aug; 363(8):779-81. PubMed ID: 20818880
    [No Abstract]   [Full Text] [Related]  

  • 18. Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma.
    Comin-Anduix B; Lee Y; Jalil J; Algazi A; de la Rocha P; Camacho LH; Bozon VA; Bulanhagui CA; Seja E; Villanueva A; Straatsma BR; Gualberto A; Economou JS; Glaspy JA; Gomez-Navarro J; Ribas A
    J Transl Med; 2008 May; 6():22. PubMed ID: 18452610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma.
    Ribas A; Comin-Anduix B; Chmielowski B; Jalil J; de la Rocha P; McCannel TA; Ochoa MT; Seja E; Villanueva A; Oseguera DK; Straatsma BR; Cochran AJ; Glaspy JA; Hui L; Marincola FM; Wang E; Economou JS; Gomez-Navarro J
    Clin Cancer Res; 2009 Oct; 15(19):6267-76. PubMed ID: 19789309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010).
    Weber J
    Oncologist; 2008; 13 Suppl 4():16-25. PubMed ID: 19001147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 483.